Divis Laboratories Ltd Share Price
As on 09 June 2026 at 22:45 IST
Divi's Laboratories Q1 FY26 Results:
Net profit rose 27% to ₹545 crores, compared to ₹430 crores in Q1 FY25. Total income in Q1 FY26 increased 15% to ₹2,529 crores from ₹2,197 crores in the same period last year.
About Divis Laboratories Ltd
Divis Laboratories Ltd was established in 1990. The company is a prominent player in the pharmaceuticals and drugs sector. Its headquarters is in Hyderabad, India. The company has decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs). It also has expertise in Nutraceutical Ingredients. They even provide Custom Synthesis of APIs for major pharmaceutical companies. The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-2.82%
Over 6 Months
3.04%
Over 1 Year
-1.69%
Over 3 Years
86.33%
Divis Laboratories Ltd Summary
Close ₹6,521
Open ₹6,571
High ₹6,710
Low ₹6,506
Volume 4,56,406
Net Turnover (in Cr) ₹301.22
52Wk High ₹7,071.50
52Wk Low ₹5,636.50
52Wk High / Low
5,636.50
7,071.50
Divis Laboratories Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹1,73,112.06
EPS (TTM) 100.29
Book Value (BV) 629.49
Div. Yield 0.46 %
P/E (TTM) 66.36
Price/Book Value 10.35
Delivery % 61.33 %
Face Value 2
Key Ratios
PE Ratio 69.26
PB Ratio 10.27
EV to Sales 16.26
PEG Ratio 1.72
ROA 14.83
ROE 15.57
Debt-Equity -
Net Profit Margin 24.02
Operating Profit Margin 36.23
Divis Laboratories Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 9,712 | 8,184 | 8,112.17 | 9,073.70 | 7,031.96 |
| Total Expenses | 6,796 | 6,021 | 5,743.54 | 5,390.20 | 4,365.92 |
| Profit Before Tax | 2,916 | 2,163 | 2,368.63 | 3,683.50 | 2,666.04 |
| Profit After Tax | 2,191 | 1,600 | 1,823.38 | 2,960.45 | 1,984.29 |
| Operating Profit After Depreciation | 2,918 | 2,166 | 2,369.30 | 3,684.30 | 2,666.91 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 5,442 | 4,739 | 4,722.60 | 4,325.05 | 3,703.87 |
| Total Non Current Assets | 6,851 | 5,795 | 5,127.03 | 5,023.21 | 4,599.36 |
| Total Current Assets | 10,081 | 9,675 | 9,311.74 | 8,351.50 | 6,174.71 |
| Total Assets | 16,932 | 15,470 | 14,438.77 | 13,374.71 | 10,774.07 |
| Total Shareholder's Fund | 14,969 | 13,571 | 12,767.09 | 11,728.18 | 9,294.61 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,653 | 1,261 | 2,459.73 | 1,911.80 | 1,946.93 |
| Net Cash Used In Investing Activities | -804 | -269 | -2,707.62 | -2,194.92 | 75.13 |
| Net Cash Used In Financing Activities | -799 | -799 | -797.17 | -532.44 | -34.89 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 9,550 | 8,002 | 7,974 | 8,991.08 | 6,861.14 |
| Total Expenses | 6,621 | 5,870 | 5,620 | 5,314.56 | 4,233.27 |
| Profit Before Tax | 2,929 | 2,132 | 2,354 | 3,676.52 | 2,627.87 |
| Profit After Tax | 2,209 | 1,576 | 1,808 | 2,948.54 | 1,954.72 |
| Operating Profit After Depreciation | 2,930 | 2,135 | 2,355 | 3,677.17 | 2,628.56 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 5,440 | 4,737 | 4,719 | 4,320.97 | 3,699.01 |
| Total Non Current Assets | 6,845 | 5,790 | 5,116 | 5,011.90 | 4,598.46 |
| Total Current Assets | 9,979 | 9,572 | 9,236 | 8,295.96 | 6,125.31 |
| Total Assets | 16,824 | 15,362 | 14,352 | 13,307.86 | 10,723.77 |
| Total Shareholder's Fund | 14,895 | 13,484 | 12,705 | 11,691.35 | 9,271.57 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,650 | 1,266 | 2,447 | 1,910.16 | 1,947.05 |
| Net Cash Used In Investing Activities | -803 | -268 | -2,707 | -2,195.40 | 75.34 |
| Net Cash Used In Financing Activities | -797 | -798 | -796 | -531.50 | -33.97 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 2,831 | 2,604 | 2,715 | 2,410 | 2,585 |
| Total Expenses | 1,897 | 1,714 | 1,827 | 1,681 | 1,699 |
| Profit Before Tax | 963 | 780 | 912 | 733 | 864 |
| Profit After Tax | 751 | 583 | 689 | 545 | 662 |
| Operating Profit after Depreciation | 1,089 | 978 | 1,033 | 848 | 972 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 2,793 | 2,578 | 2,660 | 2,357 | 2,536 |
| Total Expenses | 1,850 | 1,671 | 1,765 | 1,614 | 1,655 |
| Profit Before Tax | 971 | 798 | 920 | 747 | 861 |
| Profit After Tax | 756 | 598 | 696 | 557 | 667 |
| Operating Profit after Depreciation | 1,097 | 994 | 1,041 | 862 | 968 |
Divis Laboratories Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 6,448
S2 6,375
S3 6,244
Pivot 6,579
R1 6,652
R2 6,783
R3 6,856
Moving Average
20 SMA 6,729.93
50 SMA 6,433.50
100 SMA 6,326.81
200 SMA 6,322.19
Divis Laboratories Ltd Corporate Actions
Divis Laboratories Ltd
₹30.0/Share
Announcement Date 25 Jul 2025
Record Date 25 Jul 2025
Div Yield 1500%
Divis Laboratories Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,788.60 | ₹4,29,145.05 |
| Torrent Pharmaceuticals Ltd | ₹4,412 | ₹1,49,322.13 |
| Cipla Ltd | ₹1,388.25 | ₹1,12,149.13 |
| Zydus Lifesciences Ltd | ₹1,087.45 | ₹1,09,422.92 |
| Dr Reddys Laboratories Ltd | ₹1,275.75 | ₹1,06,482.91 |
Divis Laboratories Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| AXIS Focused Fund | 5.36% |
| SBI Multicap Fund | 2.65% |
| SBI Equity Hybrid Fund | 2.62% |
| SBI Large Cap Fund | 2.53% |
| SBI Focused Fund | 2.25% |
Divis Laboratories Ltd News
Divis Laboratories schedules AGM
On 10 August 2026
25 May 2026, 01:21 pm
Board of Divis Laboratories recommends final dividend
Of Rs 30 per share
23 May 2026, 05:13 pm
Divis Lab Q4 PAT climbs 13% YoY; recommends final dividend of Rs 30/share
Divis Laboratories reported a 13.4% YoY rise in consolidated net profit to Rs 751 crore in Q4 FY26 compared with Rs 662 crore in the same quarter last year.
23 May 2026, 03:36 pm
Divis Laboratories to table results
On 23 May 2026
14 May 2026, 04:14 pm
Divis Laboratories Ltd gains for third straight session
Divis Laboratories Ltd is quoting at Rs 6722, up 1.07% on the day as on 12:49 IST on the NSE. The stock is up 9.34% in last one year as compared to a 1.62% slide in NIFTY and a 12.19% slide in the Nifty Pharma index.
06 May 2026, 01:05 pm
Divis Laboratories Ltd Stock Analysis
- Annual revenue for Divis Laboratories Ltd increased by 19.35% to ₹9,550 crore in FY 2025 from ₹8,002 crore in FY 2024.
- Annual Net Profit for Divis Laboratories Ltd increased by 40.16% to ₹2,209 crore in FY 2025 from ₹1,576 crore in FY 2024.
- Promoter Shareholding in Divis Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 51.88% in December 2025 to 51.88% in March 2026.
- Divis Laboratories Ltd delivered a 1-year return of -1.69% compared to the Nifty 50, which provided a return of -7.89% as of the last trading session.
- Divis Laboratories Ltd share price moved up by 2.93% from its previous close of INR ₹6,521. The latest Divis Laboratories Ltd share price is INR ₹6,712.
- Divis Laboratories Ltd share price today has been at a low of 6,535 and a high of 6,790. Over the past 52 weeks, the Divis Laboratories Ltd share price has seen a low of 5,636.50 and a high of 7,071.50.
About Divis Laboratories Ltd
Divis Laboratories Ltd. was established in 1990. The company is a prominent player in the pharmaceuticals and drugs sector. Its headquarters is in Hyderabad, India. The company has decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs). It also has expertise in Nutraceutical Ingredients. They even provide Custom Synthesis of APIs for major pharmaceutical companies.
The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. Additionally, Divis Laboratories produces nutraceutical ingredients like beta-carotene and Lutein. It also produces Astaxanthin and Lycopene. The company also produces Vitamin D3 and Vitamin A. These products highlight the company’s duty to quality and innovation.
Divis Laboratories Ltd. is led by its founder and Managing Director, Dr Murali K. Divi, and the Whole-time Director, Mr Kiran S. Divi. The promoters hold a significant shareholding of approximately 51.90%. This reflects their strong commitment to the company’s growth and success. Here are the top managing promoters of the company:
The company’s first manufacturing facility was set up in 1995 at Choutuppal, Telangana. This facility marked the beginning of Divis’ journey in large-scale manufacturing. The company received ISO-9002 certification from SGS-Yarsley of the UK in 1997. This certification highlights its commitment to quality standards. By 1999, Divis Laboratories had earned a Certificate of Suitability (CoS) from the European Directorate. This certification was for the quality of its Naproxen production.
In 2002, Divis Laboratories expanded its manufacturing capabilities. They established a second facility at Chippada near Visakhapatnam. This expansion was crucial for meeting the growing global demand for APIs and intermediates. The company went public with its initial public offering (IPO) on February 17, 2003. The IPO further solidified its financial foundation and enabled future growth.
Significant milestones marked the early 2000s for Divis Laboratories. The company received multiple certifications, including ISO-14001, from SGS International AG of Switzerland. It also received OHSAS-18001 from BVQI of London. These reflect its adherence to international standards in quality and occupational health and safety. The US FDA also inspected and approved the company’s facilities. This approval underlines its compliance with stringent regulatory requirements.
In 2010, Divis Laboratories Ltd. established a research centre in Hyderabad. It was to focus on fundamental research in niche business segments. This move aimed to enhance the company’s R&D capabilities and foster innovation. Over the years, Divis Laboratories has continued to expand its product portfolio. This includes a wide range of generic APIs such as Naproxen, Gabapentin, and Dextromethorphan. It also includes Valsartan, Levetiracetam, Phenylephrine, and Pregabalin. The company also produces nutraceutical ingredients like Lutein, beta-carotene, and Lycopene. It also produces Astaxanthin, Vitamin A1, and Vitamin D3.
Divis Laboratories Ltd. has established itself as a leading manufacturer of generic APIs globally. It has a significant market share in products like Naproxen, Dextromethorphan, and Gabapentin. The company’s API production is backward integrated. This ensures a reliable supply chain and cost efficiency. Divis Laboratories also offers custom synthesis services. They provide contract development and manufacturing (CDMO) offers. It also offers contract research manufacturing services (CRAMS) for some of the world’s largest pharmaceutical companies.
The company is committed to quality, innovation, and sustainability. This has earned it many awards and recognitions from various regulatory and statutory bodies. Divis Laboratories has been honoured for its manufacturing, environment, health, and safety excellence. Today, Divis Laboratories Ltd. continues to be led by its founder, Dr Murali K. Divi, and the full-time director, Mr Kiran S. Divi. The promoters hold a large shareholding, reflecting their strong obligation to the company’s growth and success.
With many decades of experience, Divis Laboratories Ltd. remains dedicated and continue to deliver high-quality pharmaceutical products to meet global healthcare needs. The company has large-scale manufacturing capabilities. It adheres to global regulatory standards and focuses on innovation. These features position it as a significant player in the pharmaceutical industry.
The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. Additionally, Divis Laboratories produces nutraceutical ingredients like beta-carotene and Lutein. It also produces Astaxanthin and Lycopene. The company also produces Vitamin D3 and Vitamin A. These products highlight the company’s duty to quality and innovation.
Divis Laboratories Ltd. is led by its founder and Managing Director, Dr Murali K. Divi, and the Whole-time Director, Mr Kiran S. Divi. The promoters hold a significant shareholding of approximately 51.90%. This reflects their strong commitment to the company’s growth and success. Here are the top managing promoters of the company:
- Ramesh B V Nimmagadda
- Murali K Divi
- Kiran S Divi
- Nilima Prasad Divi
- S Devendra Rao
History of the Company
Dr. Murali K. Divi founded Divis Laboratories Ltd. It has grown to become a significant player in the global pharmaceutical industry. It was initially established as Divis Research Central. The company focused on developing commercial processes. This was for manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. In 1994, the company rebranded to Divis Laboratories Ltd. This signalled its intent to enter the API and intermediates manufacturing industry.The company’s first manufacturing facility was set up in 1995 at Choutuppal, Telangana. This facility marked the beginning of Divis’ journey in large-scale manufacturing. The company received ISO-9002 certification from SGS-Yarsley of the UK in 1997. This certification highlights its commitment to quality standards. By 1999, Divis Laboratories had earned a Certificate of Suitability (CoS) from the European Directorate. This certification was for the quality of its Naproxen production.
In 2002, Divis Laboratories expanded its manufacturing capabilities. They established a second facility at Chippada near Visakhapatnam. This expansion was crucial for meeting the growing global demand for APIs and intermediates. The company went public with its initial public offering (IPO) on February 17, 2003. The IPO further solidified its financial foundation and enabled future growth.
Significant milestones marked the early 2000s for Divis Laboratories. The company received multiple certifications, including ISO-14001, from SGS International AG of Switzerland. It also received OHSAS-18001 from BVQI of London. These reflect its adherence to international standards in quality and occupational health and safety. The US FDA also inspected and approved the company’s facilities. This approval underlines its compliance with stringent regulatory requirements.
In 2010, Divis Laboratories Ltd. established a research centre in Hyderabad. It was to focus on fundamental research in niche business segments. This move aimed to enhance the company’s R&D capabilities and foster innovation. Over the years, Divis Laboratories has continued to expand its product portfolio. This includes a wide range of generic APIs such as Naproxen, Gabapentin, and Dextromethorphan. It also includes Valsartan, Levetiracetam, Phenylephrine, and Pregabalin. The company also produces nutraceutical ingredients like Lutein, beta-carotene, and Lycopene. It also produces Astaxanthin, Vitamin A1, and Vitamin D3.
Divis Laboratories Ltd. has established itself as a leading manufacturer of generic APIs globally. It has a significant market share in products like Naproxen, Dextromethorphan, and Gabapentin. The company’s API production is backward integrated. This ensures a reliable supply chain and cost efficiency. Divis Laboratories also offers custom synthesis services. They provide contract development and manufacturing (CDMO) offers. It also offers contract research manufacturing services (CRAMS) for some of the world’s largest pharmaceutical companies.
The company is committed to quality, innovation, and sustainability. This has earned it many awards and recognitions from various regulatory and statutory bodies. Divis Laboratories has been honoured for its manufacturing, environment, health, and safety excellence. Today, Divis Laboratories Ltd. continues to be led by its founder, Dr Murali K. Divi, and the full-time director, Mr Kiran S. Divi. The promoters hold a large shareholding, reflecting their strong obligation to the company’s growth and success.
With many decades of experience, Divis Laboratories Ltd. remains dedicated and continue to deliver high-quality pharmaceutical products to meet global healthcare needs. The company has large-scale manufacturing capabilities. It adheres to global regulatory standards and focuses on innovation. These features position it as a significant player in the pharmaceutical industry.
FAQ’s
What is the share price of Divis Laboratories Ltd today?
Divis Laboratories Ltd share price as on 9 Jun 2026 is ₹ 6712.0
What is the Market Cap of Divis Laboratories Ltd?
The market cap of Divis Laboratories Ltd stock is ₹1,73,112.06 Cr.
What is the PE Ratio of Divis Laboratories Ltd?
The Price to Earnings (P/E) Ratio of Divis Laboratories Ltd is 69.26
What is the PB Ratio of Divis Laboratories Ltd?
The Price to Book (P/B) Ratio of Divis Laboratories Ltd is 10.27
What is the 52 week high of Divis Laboratories Ltd Share Price?
The 52 week high of Divis Laboratories Ltd share price stands at ₹7,071.50
What is the 52 week low of Divis Laboratories Ltd Share Price?
The 52 week low of Divis Laboratories Ltd share price stands at ₹5,636.50
How can I buy shares of Divis Laboratories Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Divis Laboratories Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
